Prof. dr. J.W. Jukema

Prof. dr. J.W. Jukema

Prof. dr. J.W. (Wouter) Jukema is opgeleid tot cardioloog in Amsterdam (Vrije Universiteit) en Leiden (Leids Universitair Medisch Centrum (LUMC) en is voorzitter van "Leiden Vascular Medicine" en "Established Clinical Investigator" van de Nederlandse Hartstichting. Tevens "founding director" van het in 2007 opgerichte "Durrer Institute for Cardiogenetic Research" in Amsterdam. Zijn promotieonderzoek "angiografic coronary atherosclerosis trials" verrichtte hij voornamelijk op het Interuniversitair Cardiologisch Instituut Nederland (ICIN) in Utrecht.

Zijn onderzoek en dagelijks werkt richt zich met name op athero-trombose, zowel (interventie) cardiologie als coronaire atherosclerose. Deze athero-trombose research focust op vasculaire biologie, lipoproteïnen en genetische achtergronden van athero-trombose en restenose/trombose na PTCA, zowel in mensen als in transgene dieren, en de meerderheid van zijn publicaties hebben dan ook betrekking op deze aandachtsgebieden. Hij is (hoofd)onderzoeker van meerdere internationale athero-trombose studies en lid van een aantal (inter)nationale athero-trombose- en lipiden vergaderingen. 

Top-cited publications

2455 times cited (±161/year) Source: Scopus

Lancet (London, England), Volume 360, Issue 9346, 01 November 2002, Pages 1623-1630 Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG, PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Abstract


1096 times cited (±138/year) Source: Scopus

Lancet (London, England), Volume 375, Issue 9716, 16 February 2010, Pages 735-742 Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Seshasai SR, McMurray JJ, Freeman DJ, Jukema JW, Macfarlane PW, Packard CJ, Stott DJ, Westendorp RG, Shepherd J, Davis BR, Pressel SL, Marchioli R, Marfisi RM, Maggioni AP, Tavazzi L, Tognoni G, Kjekshus J, Pedersen TR, Cook TJ, Gotto AM, Clearfield MB, Downs JR, Nakamura H, Ohashi Y, Mizuno K, Ray KK, Ford I. Abstract


809 times cited (±117/year) Source: Scopus

Nature genetics, Volume 43, Issue 4, 06 March 2011, Pages 333-338 Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Schunkert H, König IR, Kathiresan S, Reilly MP, Assimes TL, Holm H, Preuss M, Stewart AF, Barbalic M, Gieger C, Absher D, Aherrahrou Z, Allayee H, Altshuler D, Anand SS, Andersen K, Anderson JL, Ardissino D, Ball SG, Balmforth AJ, Barnes TA, Becker DM, Becker LC, Berger K, Bis JC, Boekholdt SM, Boerwinkle E, Braund PS, Brown MJ, Burnett MS, Buysschaert I, Cardiogenics, Carlquist JF, Chen L, Cichon S, Codd V, Davies RW, Dedoussis G, Dehghan A, Demissie S, Devaney JM, Diemert P, Do R, Doering A, Eifert S, Mokhtari NE, Ellis SG, Elosua R, Engert JC, Epstein SE, de Faire U, Fischer M, Folsom AR, Freyer J, Gigante B, Girelli D, Gretarsdottir S, Gudnason V, Gulcher JR, Halperin E, Hammond N, Hazen SL, Hofman A, Horne BD, Illig T, Iribarren C, Jones GT, Jukema JW, Kaiser MA, Kaplan LM, Kastelein JJ, Khaw KT, Knowles JW, Kolovou G, Kong A, Laaksonen R, Lambrechts D, Leander K, Lettre G, Li M, Lieb W, Loley C, Lotery AJ, Mannucci PM, Maouche S, Martinelli N, McKeown PP, Meisinger C, Meitinger T, Melander O, Merlini PA Abstract


Most recent publications

01 Feb 2018

Current opinion in lipidology, Volume 29, Issue 1, 01 February 2018, Pages 51-52 Plasma apolipoprotein-B is an important risk factor for cardiovascular disease, and its assessment should be routine clinical practice. Trompet S, Packard CJ, Jukema JW. Abstract


28 Dec 2017

Journal of thrombosis and haemostasis : JTH, 28 December 2017 Determinants of Impaired Renal and Vascular Function are associated with higher Levels of Procoagulant Factors in the General Population. Dekkers IA, de Mutsert R, de Vries APJ, Rosendaal FR, Cannegieter SC, Jukema JW, le Cessie S, Rabelink TJ, Lamb HJ, Lijfering WM. Abstract


11 Dec 2017

European journal of heart failure, 11 December 2017 Nuclear magnetic resonance-based metabolomics identifies phenylalanine as a novel predictor of incident heart failure hospitalisation: results from PROSPER and FINRISK 1997. Delles C, Rankin NJ, Boachie C, McConnachie A, Ford I, Kangas A, Soininen P, Trompet S, Mooijaart SP, Jukema JW, Zannad F, Ala-Korpela M, Salomaa V, Havulinna AS, Welsh P, Würtz P, Sattar N. Abstract